Verification of the versatility and safety of next-generation HDL mimetic peptides

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K08528
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 53020:Cardiology-related
• Research Institution: Fukuoka University
• Principal Investigator: Saku Keijiro 福岡大学, 医学部, 教授 (40183371)
• Co-Investigator(Kenkyū-buntansha): 三浦 伸一郎 福岡大学, 医学部, 教授 (20343709)
• Project Period (FY): 2019-04-01 – 2022-03-31
• Keywords: ApoA-I模倣ペプチド / 動脈硬化 / 抗炎症作用 / 血管新生作用 / 抗アポトーシス作用

Outline of Final Research Achievements

We verified the multi-functionality of the next-generation HDL mimetic peptide other than the inhibitory effect of arteriosclerosis. As a next-generation HDL peptide, an improved ApoA-I mimetic peptide with improved cholesterol extraction was prepared and used in the experiments. The anti-inflammatory effect was found to be induced by the improved mimetic peptide. In addition, in the anti-apoptotic effect, the improved ApoA-I mimetic peptide significantly suppressed Caspase-3 activation with HDL. The effect was superior to that of HDL alone. The angiogenic effect caused by the improved ApoA-I mimetic peptide significantly more angiogenesis than conventional mimetic peptides. We also developed a pegylated mimetic peptide with improved cholesterol extraction compared to the improved mimetic peptide. Furthermore, we created a mouse model of doxorubicin-induced cardiac dysfunction and found that the ApoA-I mimetic peptide suppresses cardiac dysfunction.

Free Research Field

動脈硬化

Academic Significance and Societal Importance of the Research Achievements

動脈硬化は、心血管病を引き起こすがその制圧は非常に重要である。しかし、その制圧は十分でない。そこで、新たな治療法が必要である。高比重リポ蛋白（HDL）は、末梢からコレステロールを引き抜き、動脈硬化を抑制するが、HDLコレステロールの量を増加させたり、機能を向上させる方法は十分でない。この次世代型HDLペプチドは、その機能を高める有用な方法となる可能性が高く、今後の研究次第では新規の有力な抗動脈硬化療法となる。